Exact Sciences Corp (MEX:EXAS)
MXN 872 0 (0%) Market Cap: 217.13 Bil Enterprise Value: 252.21 Bil PE Ratio: 0 PB Ratio: 3.40 GF Score: 80/100

Exact Sciences Corp at Raymond James Institutional Investors Conference Transcript

Mar 08, 2022 / 09:00PM GMT
Andrew Harris Cooper
Raymond James & Associates, Inc., Research Division - Senior Research Associate

Good afternoon, everybody. Thanks for joining us. I'm Andrew Cooper, the diagnostics analyst here at Raymond James. We're happy to have Exact Sciences here. We've got Jeff Elliott, CFO; we've got Megan in IR in the back as well. I'm going to hand it over to Jeff to give us a quick overview here, and then we'll jump into fireside chat in just a few minutes. So Jeff?

Jeffrey T. Elliott
Exact Sciences Corporation - Executive VP, CFO & COO

Thanks, Andrew, and thanks to all of you. It's great to be back in front of an audience in-person presenting again. Hopefully, we can keep you on this going forward.

So we are Exact scientists. We are a leading global advanced cancer diagnostics company. Today, we have about 7,000 employees around the globe. This year, we expect to do about $2 billion of revenue. Our leading products are Cologuard, which is a noninvasive test for colorectal cancer; also Oncotype, which is the primary test there is a test for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot